TORL123-002 - CATALINA-2: A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF TORL-1-23 IN WOMEN WITH ADVANCED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCERS) EXPRESSING CLAUDIN 6-0
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Why this Research Matters
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Who can Participate
Adult
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study. https://clinicaltrials.gov/study/NCT06690775?term=NCT06690775&rank=1
Study ID
Protocol Number: 25-1605
More information available at ClinicalTrials.gov: NCT06690775
Meet the Team
Principal Investigator